Efect of Quinoa and Flaxseed in Cititoxicity and Glicemic Control in Metabolic Syndrome Patients
NCT ID: NCT03915600
Last Updated: 2019-09-06
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
90 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-08-01
Study Completion Date
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The Metabolic Syndrome (MS) is a set of anthropometric alterations and chronic-degenerative diseases, such as obesity, diabetes mellitus and arterial hypertension. Each one of the diseases and physiological alterations represents a risk factor that conditions in the medium or long term another incapacitating or limiting disease that reduces the quality of life of an individual.
Our country has a growing burden of morbidity and mortality due to diseases chronic-degenerative caused, for the most part, to the unhealthy lifestyle produced by multiple factors, such as social, economic, behavioral, environmental, among others. For this reason, it is important to plan, design and implement strategies that reduce, mitigate or control this public health problem in the population. The purpose of this study is to perform a nutritional intervention that includes food such as quinoa, flaxseed or both in subjects with metabolic syndrome and follow them up for six months. The impact of this intervention will be carried out through the measurement of cytotoxicity and glycemic control, this is with the micronucleus count and the estimation of glycosylated hemoglobin (Hba1c).
This document will explain in detail what is intended to be done by presenting the following sections:
In the approach of the problem and the justification, the metabolic syndrome will be described, its impact on the Mexican population, the interest and relevance of this research project.
In the background will be detailed what has been said and done in the different studies scientists regarding the consumption of quinoa and flaxseed. Methodology defines the strategy, conditions, clinical criteria, material and epidemiological and statistical methods for the management of subjects and information.
Our country has a growing burden of morbidity and mortality due to diseases chronic-degenerative caused, for the most part, to the unhealthy lifestyle produced by multiple factors, such as social, economic, behavioral, environmental, among others. For this reason, it is important to plan, design and implement strategies that reduce, mitigate or control this public health problem in the population. The purpose of this study is to perform a nutritional intervention that includes food such as quinoa, flaxseed or both in subjects with metabolic syndrome and follow them up for six months. The impact of this intervention will be carried out through the measurement of cytotoxicity and glycemic control, this is with the micronucleus count and the estimation of glycosylated hemoglobin (Hba1c).
This document will explain in detail what is intended to be done by presenting the following sections:
In the approach of the problem and the justification, the metabolic syndrome will be described, its impact on the Mexican population, the interest and relevance of this research project.
In the background will be detailed what has been said and done in the different studies scientists regarding the consumption of quinoa and flaxseed. Methodology defines the strategy, conditions, clinical criteria, material and epidemiological and statistical methods for the management of subjects and information.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Retrospective Analysis for Patients With Metabolic Syndrome
NCT06182618
Metabolic Syndrome
RECRUITING
Effect of Moringa Oleifera Dehydrated Leaf Powder on the Components of Metabolic Syndrome in Mexican Adults.
NCT07194577
Nutritional and Metabolic Diseases
Metabolic Syndrome
COMPLETED
NA
Alpha Lipoic Acid Supplementation and Metabolic Syndrome
NCT03589690
Metabolic Syndrome
UNKNOWN
NA
Effects of Short-term Interventions for a Healthy Lifestyle on the Human Lipidome in Subjects With Metabolic Syndrome
NCT03047655
Metabolic Syndrome
NAFLD
Obesity
+1 more
UNKNOWN
NA
Telemedicine With Metabolic Syndrome
NCT05117580
Metabolic Syndrome
Life Style
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The "strong pulse disease" was treated by acupuncture, phlebotomy and leeches from 2600 to c. Modern history began when in 1628 William Harvey described the circulatory system and in 1733 stephen hales made the first blood pressure measurement. In 1896 was recognized as a clinical entity, thanks to the invention of the sphygmomanometer by Riva-rocci and in 1913 janeway coined the term "hypertensive vascular disease". The metabolic syndrome was described since 1988 as syndrome x, with the intention of showing how the cardiovascular risk factors are grouped together: obesity, hyperglycemia, dyslipidemia and arterial hypertension. Earlier, in 1920, Kylin had described that diabetes, high blood pressure and gout were associated, but not related to cardiovascular disease. Syndrome x was later called insulin resistance syndrome and, finally, metabolic syndrome or cardiometabolic syndrome. By 1999, the world health organization reported what would be the first diagnostic criteria for the metabolic syndrome. Soon they were reason for criticism because they were considered impractical, because it was necessary to diagnose insulin resistance and microalbuminuria. From then to date numerous criteria have been reported, perhaps the most used to date, in adults they are the
3.- NCEP-ATPIII (from the third treatment panel of adults of the national cholesterol education program of the United States). The main trigger of this conglomerate of atherogenic, prothrombotic, proinflammatory and metabolic factors is obesity, in our country, the prevalence of overweight and obesity in adults increased from 62 to 70% in just five years. In the last century, in Mexico the energy density of the diet was increased by almost 24% (26% more carbohydrates and 36% more fat) and physical activity has been reduced In Mexico, the prevalence of metabolic syndrome in children and adolescents is 20% and is strongly linked to overweight and childhood obesity.
Mexicans are world leaders in obesity, since one in three Mexicans is overweight due to poor diet. In February 2012, the organization for cooperation and economic development (OECD) reported that Mexico was the second most overweight or obese country on a list that includes 40 nations, adding that three out of seven Mexicans have a waistline bigger than they should be. Chronic degenerative diseases have displaced infectious diseases as the main causes of mortality in Mexico. In 2011, 70 of every 100.00 people died from this disease in the country.
In Mexico, aguilar-salinas reported an age-adjusted prevalence of 13.6% with the criterion of the world health organization and 26.6% with the ncep-atpiii criterion in people between 20 and 69 years old, from the ensa survey. -2000; while González-Villalpando in the Diabetes Study of Mexico City reported prevalences of 39.9 and 59.9% for men and women, respectively, based on the criteria of the Ncep-ATP III.
In Mexico, diabetes is the leading cause of blindness acquired in the productive age; as well it is the first cause of non-traumatic amputations of the lower limbs and of chronic renal failure. Short and long-term complications require medical attention and specialized treatments, which means that your care entails overwhelmingly high costs. The Binomial insulin resistance/hyperinsulinemia are associated with a significant increase in cardiovascular morbidity and mortality expressed as atherosclerosis, acute cerebral, cardiac or peripheral ischemic syndromes, as well as other pathologies, which due to their coexistence and physiopathological co-responsibility has been called metabolic syndrome.
In 2011 Mexico ranked ninth in the world in the prevalence of diabetes and the projections indicate that by the year 2025, the country will occupy the sixth or seventh place. Diabetes mellitus is defined as a chronic disease that involves a heterogeneous group of disorders that alter the production and use of insulin by the body. The most frequent modality is type 2, which occurs in adults, although it is increasingly appearing in young people and children. When there are sustained increases in blood glucose, decompensation and complications occur.
Therefore, although diabetes is an endocrine disease in its origin, its main manifestations are those of a metabolic disease. On average, men with diabetes die at a younger age than women (67 versus 70 years respectively) and only 20% of men who have developed this condition live more than 75 years, compared to 26% in the case of women. In a study conducted in Mexico by Arredondo and Icazaen 2011, the direct costs of care for the disease were calculated in all institutions of the health sector and private insurance, which amounted to $ 343,226,541 m.n. in terms of indirect costs, they were estimated around $ 778,427, 475 m.n. It is important to emphasize that for every 100 pesos spent on diabetes in Mexico, approximately 51 pesos comes from households / family income, which represents a social burden of very high impact. Regarding direct costs, of every 100 pesos spent on diabetes in Mexico, 52 are spent on 10% of the population, 33 on 48% (insured) of the population and 15 pesos on the remaining 42% of the population. population (uninsured), so, in terms of allocation and flow of economic resources, the problems of inequity and access to health are evident depending on the group to which the patients and their families belong.
During the last decades, mortality due to cardiovascular diseases has increased, until it has become the leading cause of death in the United Mexican States.
Atherosclerosis is among the main causes for the development of these diseases. Atherosclerosis plays a central role in three of the first five causes of death in Mexico. Atherosclerosis is a multifactorial process caused by risk factors that damage the endothelium chronically. Among which are the age, inheritance, smoking, sedentary lifestyle, unhealthy diet, elevation of systemic blood pressure, overweight and obesity, elevation of glucose levels as well as inadequate serum lipid levels. Dyslipidemias are one of the main modifiable factors of cardiovascular risk. The scrutiny and treatment of dyslipidemias is cost-effective in the entire population over 20 years of age. In addition, dyslipidemias and arterial hypertension are frequently associated and have a synergistic effect on cardiovascular risk. The results of the national health and nutrition survey 2006, show that overweight and obesity are problems that affect 70% of the population between 30 and 65 years of age, the prevalence of diabetes by previous medical diagnosis and of finding of the survey in adults at national level was 14.42%, the prevalence of hypertension was 30.8%. The general prevalence of hypercholesterolemia was 26.5%, with 28.8% in women and 22.7% in men.
Situation of overweight and obesity. A reflection of national nutrition surveys in Mexico. In 2006, according to the results of the ENSANUT, one in three men or women Teenagers are overweight or obese. This represents around 5,757, 400 adolescents in the country. The prevalence of overweight and obesity of women aged 12 to 19 in 2006 was compared with that of 1999, using the criteria proposed by the IOTF. There is a modest increase in overweight from 21.6 to 23.3 (7.8%) and a small absolute increase, but high in relative terms, in obesity: from 6.9 to 9.2 (33.3%). The prevalence of overweight, but especially that of obesity, tended to increase with age up to 60 years; in ages of 60, 70 and over 80 years, the trend of both conditions decreased, both in men and women.
Quinoa The quinoa (chenopodium quinoa willd., Amaranthaceae), an ancient crop of the mountains of the Andes of South America, has quickly gained popularity as a food functional and nutraceutical. Due to its properties the organization of agriculture and food nations launched the international year of quinoa in 2013 to promote global production, consumption, preservation and development of the biodiversity of this crop. It has more than three thousand varieties or ecotypes, both cultivated and wild, that can be summarized in five basic categories according to the altitudinal gradient: ecotypes of the sea level, the altiplano, the inter-Andean valleys, the salt flats and the yungas. It is a grain that has outstanding intrinsic characteristics, such as: its wide genetic variability, whose genetic pool is extraordinarily strategic to develop superior varieties (precocity, color and grain size, resistance to biotic and abiotic factors, the yield of grain and by-products). It has a protein of high biological value for its high content of lysine and its balance of essential amino acids, is comparable to animal protein. It is widely used, both in human and animal feed, using the leaves and tender stems as leafy vegetables, until the phase of the beginning of the panning, then the tender panicles are consumed in replacement of inflorescence vegetables, and the ripe grain, directly or processed.
Minerals: magnesium, zinc, iron and potassium. Unfortunately, quinoa contains phytic acid that can break down these minerals and reduce their absorption digestive touch.
Fitoecdisteroides: containing a wide range of therapeutic effects in mammals, including anabolic, increasing in performance, anti osteoporotic, and wound healing property.
flavonoids: these are natural antioxidants of plants, which provide multiple health benefits. Two of the best known flavonoids are kaempferol and quercetin, which is found in large quantities in quinoa. The amount of quercetin present in quinoa is higher than high superfoods in quercetin such as blueberries. These molecules have been shown to have anti-inflammatory, antiviral, anti-depressant, anti-carcinogenic properties, although until now only in animal studies. There is a lack of studies in humans.
Antioxidants This implies that you have several substances that help you get rid of free radicals, which are responsible for aging and cardiovascular diseases and cancer. In a comparison study between 10 foods it was found that quinoa had the highest amount of antioxidants.
Flaxseed Flaxseed corresponds to the flax seed (linum usitatissimum L.) and has been traditionally used as an oilseed. In recent decades there has been great interest in it due to the recognition that some of its components offer potential benefits for the maintenance of health and the prevention of some chronic noncommunicable diseases. Among these compounds with biological activity include alpha-linolenic acid, lignans and dietary fiber. Flax seed contains various compounds that can offer health benefits such as reduced risk of developing cardiovascular diseases, mitigating the effects of diabetes, kidney diseases, obesity, cancer of the colon and rectum, reduction of serum cholesterol level and promotion of intestinal evacuation.
Functional foods are foods that resemble traditional ones, but that differ from them in that they offer benefits beyond their nutritional and energetic value, in the promotion and prevention of some chronic diseases such as cardiovascular diseases, cancer, disorders of the autoimmune system , diabetes, arthritis and arrhythmia.
In recent years, the use of linseed (Linum usitatissimum L.) has been promoted as a functional food for its health benefits, mainly attributable to its content of omega-3 fatty acids, lignans, and dietary fiber (Ostojich, 2012). Due to its exclusive nutrient profile and its potential to affect the risk and development of cardiovascular diseases and some cancers, especially those dependent on hormones such as breast and prostate, it was also found effective in reducing the levels of hemoglobin A1c and cholesterol in individuals with cholesterol and high blood sugar.
Cytotoxicity and micronuclei in oral mucosa. The micronuclei are complete chromosomes or fragments of these that remain outside the cell nucleus during mitosis, the study of these can give information about the cytotoxicity, as well as environmental effects, as occupational. Cytotoxicity is mediated by intrinsic and environmental elements in which the individual is exposed, such is the case of the increased presence of micronuclei in metabolic syndrome as in diabetic patients, in the literature it has been reported that the consumption of foods rich in antioxidants could decrease the number of micronuclei.
The oral cavity has been described as a tissue in which changes associated with illness can be observed, as well as exposure to tobacco, alcoholism, or other harmful substances, as well as various entities where there are deficiencies of vitamins and antioxidants, can also assess side effects of exposure to chemotherapy or radiotherapy because the latter can affect the proliferative capacity of epithelial cells and even of the oropharyngeal tissue that can reach ulcers due to thinning.
The characteristics that can be observed in the micronucleus test are the following:
Normal cells: the nucleus of these is uniformly dyed, it can be round or oval. These cells are considered as totally differentiated cells and no cell divisions are observed.
Micronucleated cell (cmn): characterized by the presence of a main nucleus and one or more small nuclear structures called micronuclei. A micronucleus is round or almond shaped and measures between 1/3 and 1/16 of the main nucleus, has the same intensity in focal plane as the nucleus and is a fragment or a complete chromosome that at the time of mitosis is not integrated into the nucleus. one of the nuclei of the daughter cells.
Binucleate cell (bn): are cells that contain two main nuclei, usually the nuclei are very close and could even make contact, both with morphology and staining similar to a normal nucleus and there could be two cells with double genetic material.
There are few studies that include the micronucleus technique as a tool to evaluate cellular cytotoxicity in patients with metabolic syndrome or diabetes mellitus. In 2011, Andreassi et al. Studied the frequency of micronuclei in patients with obesity, diabetes and cardiovascular disease, finding greater genetic damage assessed by comet assay and micronuclei, to the group of diabetic patients and those with cardiovascular damage compared to healthy subjects ( p \<0.0001 in micronucleated binuclear cells) and longer tails in patients with diabetes with cardiovascular damage compared to clinically healthy controls (p = 0.01).
In 2015, a study was conducted by Harishankar et al., Where they evaluated patients with diabetes mellitus treated with metformin and glimepiride by means of the micronucleus test in exfoliated urothelial cells, finding that those patients treated with metformin and glimepirin obtained a higher quantity of micronuclei. In comparison with healthy controls (p = 0.001) and those treated with only metformin and metformin with glimepirine, were the groups of subjects with the most micronuclei obtained, it is important to mention that they used two methods with clear field and with fluorescence stained with iodide of propidium not finding differences between both study techniques (Harishankar, 2015).
Karaman et al., In 2015, studied cytotoxic damage by comet and micronucleus assays, finding that patients with metabolic syndrome had longer tails in the comet assay (p \<0.001) and also a higher number of micronuclei (p \<0.001) in this same group compared to the control group.
So it would be very important to evaluate if the amount of micronuclei decreases when the patient performs a diet rich in antioxidants, because it is not yet identified if this could not only help the decrease of clinical parameters such as lipid profile, glycemic, BMI , among others; but to identify if cytotoxicity also decreases.
3.- NCEP-ATPIII (from the third treatment panel of adults of the national cholesterol education program of the United States). The main trigger of this conglomerate of atherogenic, prothrombotic, proinflammatory and metabolic factors is obesity, in our country, the prevalence of overweight and obesity in adults increased from 62 to 70% in just five years. In the last century, in Mexico the energy density of the diet was increased by almost 24% (26% more carbohydrates and 36% more fat) and physical activity has been reduced In Mexico, the prevalence of metabolic syndrome in children and adolescents is 20% and is strongly linked to overweight and childhood obesity.
Mexicans are world leaders in obesity, since one in three Mexicans is overweight due to poor diet. In February 2012, the organization for cooperation and economic development (OECD) reported that Mexico was the second most overweight or obese country on a list that includes 40 nations, adding that three out of seven Mexicans have a waistline bigger than they should be. Chronic degenerative diseases have displaced infectious diseases as the main causes of mortality in Mexico. In 2011, 70 of every 100.00 people died from this disease in the country.
In Mexico, aguilar-salinas reported an age-adjusted prevalence of 13.6% with the criterion of the world health organization and 26.6% with the ncep-atpiii criterion in people between 20 and 69 years old, from the ensa survey. -2000; while González-Villalpando in the Diabetes Study of Mexico City reported prevalences of 39.9 and 59.9% for men and women, respectively, based on the criteria of the Ncep-ATP III.
In Mexico, diabetes is the leading cause of blindness acquired in the productive age; as well it is the first cause of non-traumatic amputations of the lower limbs and of chronic renal failure. Short and long-term complications require medical attention and specialized treatments, which means that your care entails overwhelmingly high costs. The Binomial insulin resistance/hyperinsulinemia are associated with a significant increase in cardiovascular morbidity and mortality expressed as atherosclerosis, acute cerebral, cardiac or peripheral ischemic syndromes, as well as other pathologies, which due to their coexistence and physiopathological co-responsibility has been called metabolic syndrome.
In 2011 Mexico ranked ninth in the world in the prevalence of diabetes and the projections indicate that by the year 2025, the country will occupy the sixth or seventh place. Diabetes mellitus is defined as a chronic disease that involves a heterogeneous group of disorders that alter the production and use of insulin by the body. The most frequent modality is type 2, which occurs in adults, although it is increasingly appearing in young people and children. When there are sustained increases in blood glucose, decompensation and complications occur.
Therefore, although diabetes is an endocrine disease in its origin, its main manifestations are those of a metabolic disease. On average, men with diabetes die at a younger age than women (67 versus 70 years respectively) and only 20% of men who have developed this condition live more than 75 years, compared to 26% in the case of women. In a study conducted in Mexico by Arredondo and Icazaen 2011, the direct costs of care for the disease were calculated in all institutions of the health sector and private insurance, which amounted to $ 343,226,541 m.n. in terms of indirect costs, they were estimated around $ 778,427, 475 m.n. It is important to emphasize that for every 100 pesos spent on diabetes in Mexico, approximately 51 pesos comes from households / family income, which represents a social burden of very high impact. Regarding direct costs, of every 100 pesos spent on diabetes in Mexico, 52 are spent on 10% of the population, 33 on 48% (insured) of the population and 15 pesos on the remaining 42% of the population. population (uninsured), so, in terms of allocation and flow of economic resources, the problems of inequity and access to health are evident depending on the group to which the patients and their families belong.
During the last decades, mortality due to cardiovascular diseases has increased, until it has become the leading cause of death in the United Mexican States.
Atherosclerosis is among the main causes for the development of these diseases. Atherosclerosis plays a central role in three of the first five causes of death in Mexico. Atherosclerosis is a multifactorial process caused by risk factors that damage the endothelium chronically. Among which are the age, inheritance, smoking, sedentary lifestyle, unhealthy diet, elevation of systemic blood pressure, overweight and obesity, elevation of glucose levels as well as inadequate serum lipid levels. Dyslipidemias are one of the main modifiable factors of cardiovascular risk. The scrutiny and treatment of dyslipidemias is cost-effective in the entire population over 20 years of age. In addition, dyslipidemias and arterial hypertension are frequently associated and have a synergistic effect on cardiovascular risk. The results of the national health and nutrition survey 2006, show that overweight and obesity are problems that affect 70% of the population between 30 and 65 years of age, the prevalence of diabetes by previous medical diagnosis and of finding of the survey in adults at national level was 14.42%, the prevalence of hypertension was 30.8%. The general prevalence of hypercholesterolemia was 26.5%, with 28.8% in women and 22.7% in men.
Situation of overweight and obesity. A reflection of national nutrition surveys in Mexico. In 2006, according to the results of the ENSANUT, one in three men or women Teenagers are overweight or obese. This represents around 5,757, 400 adolescents in the country. The prevalence of overweight and obesity of women aged 12 to 19 in 2006 was compared with that of 1999, using the criteria proposed by the IOTF. There is a modest increase in overweight from 21.6 to 23.3 (7.8%) and a small absolute increase, but high in relative terms, in obesity: from 6.9 to 9.2 (33.3%). The prevalence of overweight, but especially that of obesity, tended to increase with age up to 60 years; in ages of 60, 70 and over 80 years, the trend of both conditions decreased, both in men and women.
Quinoa The quinoa (chenopodium quinoa willd., Amaranthaceae), an ancient crop of the mountains of the Andes of South America, has quickly gained popularity as a food functional and nutraceutical. Due to its properties the organization of agriculture and food nations launched the international year of quinoa in 2013 to promote global production, consumption, preservation and development of the biodiversity of this crop. It has more than three thousand varieties or ecotypes, both cultivated and wild, that can be summarized in five basic categories according to the altitudinal gradient: ecotypes of the sea level, the altiplano, the inter-Andean valleys, the salt flats and the yungas. It is a grain that has outstanding intrinsic characteristics, such as: its wide genetic variability, whose genetic pool is extraordinarily strategic to develop superior varieties (precocity, color and grain size, resistance to biotic and abiotic factors, the yield of grain and by-products). It has a protein of high biological value for its high content of lysine and its balance of essential amino acids, is comparable to animal protein. It is widely used, both in human and animal feed, using the leaves and tender stems as leafy vegetables, until the phase of the beginning of the panning, then the tender panicles are consumed in replacement of inflorescence vegetables, and the ripe grain, directly or processed.
Minerals: magnesium, zinc, iron and potassium. Unfortunately, quinoa contains phytic acid that can break down these minerals and reduce their absorption digestive touch.
Fitoecdisteroides: containing a wide range of therapeutic effects in mammals, including anabolic, increasing in performance, anti osteoporotic, and wound healing property.
flavonoids: these are natural antioxidants of plants, which provide multiple health benefits. Two of the best known flavonoids are kaempferol and quercetin, which is found in large quantities in quinoa. The amount of quercetin present in quinoa is higher than high superfoods in quercetin such as blueberries. These molecules have been shown to have anti-inflammatory, antiviral, anti-depressant, anti-carcinogenic properties, although until now only in animal studies. There is a lack of studies in humans.
Antioxidants This implies that you have several substances that help you get rid of free radicals, which are responsible for aging and cardiovascular diseases and cancer. In a comparison study between 10 foods it was found that quinoa had the highest amount of antioxidants.
Flaxseed Flaxseed corresponds to the flax seed (linum usitatissimum L.) and has been traditionally used as an oilseed. In recent decades there has been great interest in it due to the recognition that some of its components offer potential benefits for the maintenance of health and the prevention of some chronic noncommunicable diseases. Among these compounds with biological activity include alpha-linolenic acid, lignans and dietary fiber. Flax seed contains various compounds that can offer health benefits such as reduced risk of developing cardiovascular diseases, mitigating the effects of diabetes, kidney diseases, obesity, cancer of the colon and rectum, reduction of serum cholesterol level and promotion of intestinal evacuation.
Functional foods are foods that resemble traditional ones, but that differ from them in that they offer benefits beyond their nutritional and energetic value, in the promotion and prevention of some chronic diseases such as cardiovascular diseases, cancer, disorders of the autoimmune system , diabetes, arthritis and arrhythmia.
In recent years, the use of linseed (Linum usitatissimum L.) has been promoted as a functional food for its health benefits, mainly attributable to its content of omega-3 fatty acids, lignans, and dietary fiber (Ostojich, 2012). Due to its exclusive nutrient profile and its potential to affect the risk and development of cardiovascular diseases and some cancers, especially those dependent on hormones such as breast and prostate, it was also found effective in reducing the levels of hemoglobin A1c and cholesterol in individuals with cholesterol and high blood sugar.
Cytotoxicity and micronuclei in oral mucosa. The micronuclei are complete chromosomes or fragments of these that remain outside the cell nucleus during mitosis, the study of these can give information about the cytotoxicity, as well as environmental effects, as occupational. Cytotoxicity is mediated by intrinsic and environmental elements in which the individual is exposed, such is the case of the increased presence of micronuclei in metabolic syndrome as in diabetic patients, in the literature it has been reported that the consumption of foods rich in antioxidants could decrease the number of micronuclei.
The oral cavity has been described as a tissue in which changes associated with illness can be observed, as well as exposure to tobacco, alcoholism, or other harmful substances, as well as various entities where there are deficiencies of vitamins and antioxidants, can also assess side effects of exposure to chemotherapy or radiotherapy because the latter can affect the proliferative capacity of epithelial cells and even of the oropharyngeal tissue that can reach ulcers due to thinning.
The characteristics that can be observed in the micronucleus test are the following:
Normal cells: the nucleus of these is uniformly dyed, it can be round or oval. These cells are considered as totally differentiated cells and no cell divisions are observed.
Micronucleated cell (cmn): characterized by the presence of a main nucleus and one or more small nuclear structures called micronuclei. A micronucleus is round or almond shaped and measures between 1/3 and 1/16 of the main nucleus, has the same intensity in focal plane as the nucleus and is a fragment or a complete chromosome that at the time of mitosis is not integrated into the nucleus. one of the nuclei of the daughter cells.
Binucleate cell (bn): are cells that contain two main nuclei, usually the nuclei are very close and could even make contact, both with morphology and staining similar to a normal nucleus and there could be two cells with double genetic material.
There are few studies that include the micronucleus technique as a tool to evaluate cellular cytotoxicity in patients with metabolic syndrome or diabetes mellitus. In 2011, Andreassi et al. Studied the frequency of micronuclei in patients with obesity, diabetes and cardiovascular disease, finding greater genetic damage assessed by comet assay and micronuclei, to the group of diabetic patients and those with cardiovascular damage compared to healthy subjects ( p \<0.0001 in micronucleated binuclear cells) and longer tails in patients with diabetes with cardiovascular damage compared to clinically healthy controls (p = 0.01).
In 2015, a study was conducted by Harishankar et al., Where they evaluated patients with diabetes mellitus treated with metformin and glimepiride by means of the micronucleus test in exfoliated urothelial cells, finding that those patients treated with metformin and glimepirin obtained a higher quantity of micronuclei. In comparison with healthy controls (p = 0.001) and those treated with only metformin and metformin with glimepirine, were the groups of subjects with the most micronuclei obtained, it is important to mention that they used two methods with clear field and with fluorescence stained with iodide of propidium not finding differences between both study techniques (Harishankar, 2015).
Karaman et al., In 2015, studied cytotoxic damage by comet and micronucleus assays, finding that patients with metabolic syndrome had longer tails in the comet assay (p \<0.001) and also a higher number of micronuclei (p \<0.001) in this same group compared to the control group.
So it would be very important to evaluate if the amount of micronuclei decreases when the patient performs a diet rich in antioxidants, because it is not yet identified if this could not only help the decrease of clinical parameters such as lipid profile, glycemic, BMI , among others; but to identify if cytotoxicity also decreases.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Metabolic Syndrome
Nutritional and Metabolic Diseases
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
An open clinical trial with randomization plus control group
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Quinoa
Personalized diet added with quinoa
Group Type
EXPERIMENTAL
Quinoa
Intervention Type
OTHER
Personalized diet added with quinoa
Flaxseed
Personalized diet added with Flaxseed
Group Type
EXPERIMENTAL
Flaxseed
Intervention Type
OTHER
personalized diet added with flaxseed
Quinoa and Flaxseed
Personalized diet added with quinoa and flaxseed
Group Type
EXPERIMENTAL
Quinoa and Flaxseed
Intervention Type
OTHER
personalized diet added with quinoa and flaxseed
Normal diet
Personalized diet without dietary supplement
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quinoa
Personalized diet added with quinoa
Intervention Type
OTHER
Flaxseed
personalized diet added with flaxseed
Intervention Type
OTHER
Quinoa and Flaxseed
personalized diet added with quinoa and flaxseed
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnostic of Metabolic Syndrome that meets at least one of the ATP-III criteria:
* Abdominal obesity over 102cm for men and over 88cm for women
* Triglycerides levels over 150mg/dl with or without treatment for dyslipidemia
* c-HDL concentration under 40mg/dl for men and under 50mg/dl for women
* Blood Pressure over 130/85mmHg
* Fasting glucose levels over 100mg/dl with or without treatment
* Abdominal obesity over 102cm for men and over 88cm for women
* Triglycerides levels over 150mg/dl with or without treatment for dyslipidemia
* c-HDL concentration under 40mg/dl for men and under 50mg/dl for women
* Blood Pressure over 130/85mmHg
* Fasting glucose levels over 100mg/dl with or without treatment
Exclusion Criteria
* Pregnant women
* Subject with other degenerative chronic diseases does not include or consider it in ATP-III criteria for Metabolic Syndrome
Elimination Criteria
* Subjects without oral mucosa samples
* Subjects without A1c data
* Subjects without addiction to treatment under 80% with quinoa, flaxseed or both and conventional diet
* Subject with other degenerative chronic diseases does not include or consider it in ATP-III criteria for Metabolic Syndrome
Elimination Criteria
* Subjects without oral mucosa samples
* Subjects without A1c data
* Subjects without addiction to treatment under 80% with quinoa, flaxseed or both and conventional diet
Minimum Eligible Age
30 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Civil de Guadalajara
OTHER
Sponsor Role
collaborator
University of Guadalajara
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ana Lilia Fletes Rayas
PROFESSOR ASSOCIATE TYPE A
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ana Lilia Fletes Rayas, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Guadalajara
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Civil de Guadalajara "Fray Antonio Alcalde"
Guadalajara, Jalisco, Mexico
Site Status
RECRUITING
Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara
Guadalajara, Jalisco, Mexico
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Mexico
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Claudia Elizabeth Granados Manzo, N.E.N.C.
Role: primary
+52 3312656388
References
Explore related publications, articles, or registry entries linked to this study.
Andreassi MG, Barale R, Iozzo P, Picano E. The association of micronucleus frequency with obesity, diabetes and cardiovascular disease. Mutagenesis. 2011 Jan;26(1):77-83. doi: 10.1093/mutage/geq077.
Reference Type
BACKGROUND
Berti C, Riso P, Monti LD, Porrini M. In vitro starch digestibility and in vivo glucose response of gluten-free foods and their gluten counterparts. Eur J Nutr. 2004 Aug;43(4):198-204. doi: 10.1007/s00394-004-0459-1. Epub 2004 Jan 6.
Reference Type
BACKGROUND
Graf BL, Poulev A, Kuhn P, Grace MH, Lila MA, Raskin I. Quinoa seeds leach phytoecdysteroids and other compounds with anti-diabetic properties. Food Chem. 2014 Nov 15;163:178-85. doi: 10.1016/j.foodchem.2014.04.088. Epub 2014 May 4.
Reference Type
BACKGROUND
Ezzati M, Riboli E. Behavioral and dietary risk factors for noncommunicable diseases. N Engl J Med. 2013 Sep 5;369(10):954-64. doi: 10.1056/NEJMra1203528. No abstract available.
Reference Type
BACKGROUND
Karaman A, Aydin H, Geckinli B, Cetinkaya A, Karaman S. DNA damage is increased in lymphocytes of patients with metabolic syndrome. Mutat Res Genet Toxicol Environ Mutagen. 2015 Apr;782:30-5. doi: 10.1016/j.mrgentox.2015.03.009. Epub 2015 Mar 13.
Reference Type
BACKGROUND
Leon-Munoz LM, Guallar-Castillon P, Lopez Garcia E, Banegas JR, Gutierrez-Fisac JL, Rodriguez-Artalejo F. Relationship of BMI, waist circumference, and weight change with use of health services by older adults. Obes Res. 2005 Aug;13(8):1398-404. doi: 10.1038/oby.2005.169.
Reference Type
BACKGROUND
Penarrieta JM, Alvarado JA, Akesson B, Bergenstahl B. Total antioxidant capacity and content of flavonoids and other phenolic compounds in canihua (Chenopodium pallidicaule): an Andean pseudocereal. Mol Nutr Food Res. 2008 Jun;52(6):708-17. doi: 10.1002/mnfr.200700189.
Reference Type
BACKGROUND
Rajesha J, Murthy KN, Kumar MK, Madhusudhan B, Ravishankar GA. Antioxidant potentials of flaxseed by in vivo model. J Agric Food Chem. 2006 May 31;54(11):3794-9. doi: 10.1021/jf053048a.
Reference Type
BACKGROUND
Ranilla LG, Apostolidis E, Genovese MI, Lajolo FM, Shetty K. Evaluation of indigenous grains from the Peruvian Andean region for antidiabetes and antihypertension potential using in vitro methods. J Med Food. 2009 Aug;12(4):704-13. doi: 10.1089/jmf.2008.0122.
Reference Type
BACKGROUND
Stewart LK, Soileau JL, Ribnicky D, Wang ZQ, Raskin I, Poulev A, Majewski M, Cefalu WT, Gettys TW. Quercetin transiently increases energy expenditure but persistently decreases circulating markers of inflammation in C57BL/6J mice fed a high-fat diet. Metabolism. 2008 Jul;57(7 Suppl 1):S39-46. doi: 10.1016/j.metabol.2008.03.003.
Reference Type
BACKGROUND
Voss S, Hesse A, Zimmermann DJ, Sauerbruch T, von Unruh GE. Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test. J Urol. 2006 May;175(5):1711-5. doi: 10.1016/S0022-5347(05)01001-3.
Reference Type
BACKGROUND
Hou Y, Aboukhatwa MA, Lei DL, Manaye K, Khan I, Luo Y. Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacology. 2010 May;58(6):911-20. doi: 10.1016/j.neuropharm.2009.11.002. Epub 2009 Nov 14.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://www.dof.gob.mx/nota_detalle.php?codigo=5259329&fecha=13/07/2012
NORMA Oficial Mexicana NOM-037-SSA2-2012, Para la prevención, tratamiento y control de las dislipidemias.
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112017000100020
Diferencias entre la prevalencia de obesidad y exceso de peso estimadas con datos declarados o por medición directa en adultos de la Comunidad Valenciana
https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0717-95022013000200050
Utilidad de la Prueba de Micronúcleos y Anormalidades Nucleares en Células Exfoliadas de Mucosa Oral en la Evaluación de Daño Genotóxico y Citotóxico
http://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=41887
Procedimientos básicos de la prueba de micronúcleos y anormalidades nucleares en células exfoliadas de mucosa oral
http://www.revespcardiol.org/es/una-nueva-definicion-mundial-del/articulo/13082533/
Una nueva definición mundial del síndrome metabólico propuesta por la Federación Internacional de Diabetes: fundamento y resultados
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
235/15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Impact of Interventions With a Diet and Exercise on the Cardio-metabolic Status in Multi-risk Population
NCT03701425
UNKNOWN
NA
Effect of Two Diets With Different Content of Protein on Weight Loss in Adults With Metabolic Syndrome
NCT02278757
COMPLETED
NA
Impact of a Nutritional Intervention on Type1 Diabetes Adult With Metabolic Syndrome
NCT02821585
COMPLETED
NA
The Effectiveness of Intermittent Fasting, Caloric Restriction and Physical Activity On Metabolic Syndrome
NCT07181655
RECRUITING
NA
Effect of a Treatment of Lifestyle Changes on the Prevalence of Metabolic Syndrome and Body Weight in Mexican Women
NCT02247635
COMPLETED
NA
Hämeenlinna Metabolic Syndrome Research Program: Oxidized LDL and Arterial Elasticity in Metabolic Syndrome and Controls (HMS-01)
NCT01114763
COMPLETED
Hämeenlinna Metabolic Syndrome Research Program: Surrogate Indicators for Atherosclerosis
NCT01119404
UNKNOWN
Effect of a Low Glycemic Index on Metabolic Syndrome
NCT02356952
COMPLETED
NA
Design of a Genetic Score to Predict the Response to a Dietary Intervention in Adults With Metabolic Syndrome
NCT05495074
UNKNOWN
NA
Effectiveness of a Lifestyle Intervention on Metabolic Syndrome.
NCT03416439
COMPLETED
PHASE3
Effectiveness of MD on MetS Patients
NCT06961682
NOT_YET_RECRUITING
NA
Type 2 Diabetes and Associated Factors in Mexico
NCT07248891
ENROLLING_BY_INVITATION
Metabolic Syndrome and Fingertip Endothelial Dysfunction
NCT01007227
COMPLETED
NA
Cardiometabolic Syndrome Response to Therapeutic Lifestyle Changes
NCT04093440
UNKNOWN
NA
Reduction of the Metabolic Syndrome in Navarra-Spain
NCT01087086
COMPLETED
NA
Metabolic Syndrome Diagnosis and Treatment for Adults of Low Socioeconomic Status Communities
NCT02459249
UNKNOWN
NA
Effect of Diabetes-Specific Nutrition Formula on the Metabolic Parameters of Filipino Adults with Metabolic Syndrome
NCT06729008
NOT_YET_RECRUITING
NA
"The Effect of Comprehensive Non-pharmacological Treatment on Metabolic Disorders in Type 2 Diabetic Patients"
NCT04632823
UNKNOWN
NA
The Reversal Intervention for Metabolic Syndrome Study
NCT01043770
COMPLETED
NA
The Effect of Mastiha Oil in Metabolic Syndrome
NCT04785573
COMPLETED
NA
A Tailored, Optimised, and Person-centred Programme to Promote Lifestyle Modification in People With Metabolic Syndrome
NCT06793930
RECRUITING
NA
Food Supplement for Individuals with Metabolic Syndrome
NCT06647108
NOT_YET_RECRUITING
NA
SUMCO Metabolic Syndrome Project
NCT01278628
COMPLETED
PHASE1
Integrating Lifestyle Therapy for Diabetes Prevention Into Primary Care
NCT00853801
COMPLETED
NA